The targeted introduction of mutations utilizing sequence specific transcription activator-like effector nucleases (TALENs) and the clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated (Cas) 9 system (RNA-guided nucleases, RGNs) has revolutionized reverse genetic approaches in numerous model organisms.
A portion of the RS2 gene [GenBank: EU651888] was screened for mutations utilizing the TILLING strategy [ 4]; four lines were identified which contained single nucleotide polymorphisms (SNPs).
Several commercial assay kits, such as the Ipsogen MutaScreen, have been introduced for the sensitive semiquantification of JAK2 V617F and common MPL mutations utilizing the minor grove binder (MGB) probe.
Note that while most of the mutations utilized here have been described in multiple VHL families, a few of the mutations (used here and in other reports) are not especially common and have been classified based on a single family.
Since the majority of the type 1 VHL mutations utilized so far in our assays were major alterations in pVHL, additional type 1 VHL mutations, all missense (S65W, N78S, and L158P), were studied.
Thus, utilizing a mutation rate of 2.0 × 10-8 to account for elevated sequence evolution of Ty3/gypsy-like retrotransposons, proliferation events indicated by peaks at 0.02 to 0.04 divergence are roughly estimated to have occurred some 0.5 to 1 million years ago.
To identify the chromosomal location of the feelgood mutation, we utilized a positional cloning strategy.
We have sequenced the promoter, exons, and splice junctions of FMR1 in 51 unrelated patients with several classic features of FXS but without the full mutation utilizing resequencing arrays.
To explore whether ubiquitin modification of VHL leads to nuclear export and SUMO modification results in nuclear import, as well as whether ubiquitylation and SUMOylation of VHL exhibits distinct protein stability, we engineered the ubiquitin and SUMO modified VHL (VHL-UbΔGG and VHL-SUMO1ΔC4) with a mutation in lysine 171 by utilizing an artificially fused protein strategy [32].
The analysis of the COL4A2 G702D mutation performed here utilized a combination of skin biopsies and primary dermal fibroblasts.
